USPTO Examiner AEDER SEAN E - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18991315Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofDecember 2024March 2025Allow310NoNo
18628200RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSApril 2024February 2025Allow1110NoNo
18592208METHODS OF TREATING TUMORFebruary 2024March 2025Allow1210NoNo
18408377METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICSJanuary 2024November 2024Allow1010YesNo
18396461ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYDecember 2023January 2025Allow1310NoNo
18542441T CELL RECEPTORS AND FUSION PROTEINS THEREOFDecember 2023April 2024Allow400NoNo
18537973COMPOSITION OF BL-8040December 2023October 2024Allow1020YesNo
18532450SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERSDecember 2023March 2025Allow1621NoNo
18531287DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESDecember 2023August 2024Abandon800NoNo
18529758COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSDecember 2023February 2025Allow1420NoNo
18516168RESPONSE TO EGFR BLOCKADENovember 2023April 2025Abandon1710NoNo
18487818METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHOctober 2023April 2025Abandon1810NoNo
18475552Anti-TIM-3 Antibodies and Use ThereofSeptember 2023February 2025Abandon1710NoNo
18471388HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USESeptember 2023March 2024Allow610YesNo
18462648OVARIAN CANCER VACCINESSeptember 2023March 2025Allow1820NoNo
18463209HETERODIMERIC PROTEINSSeptember 2023May 2025Allow2010NoNo
18459857Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofSeptember 2023June 2024Abandon1010NoNo
18456044NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAMEAugust 2023May 2025Allow2130NoNo
18263430ANTI-NECTIN-4-ANTIBODIES AND USES THEREOFJuly 2023March 2024Allow810NoNo
18270521COMPOSITION OF BL-8040June 2023January 2025Allow1910NoNo
18340774NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLIGHTING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOFJune 2023December 2023Allow500NoNo
18213132HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOFJune 2023February 2025Allow2020NoNo
18211038Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses ThereofJune 2023January 2025Allow1920NoNo
18325497BIOMARKERS FOR CANCER IMMUNOTHERAPY OUTCOMESMay 2023January 2025Abandon1901NoNo
18200000ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND CHEMOTHERAPEUTIC AGENTMay 2023January 2025Allow2060NoNo
18036610METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHMay 2023May 2025Abandon2520YesNo
18308623HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSApril 2023March 2025Allow2211NoNo
18134293METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPYApril 2023December 2024Abandon2010NoNo
18133822TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIESApril 2023September 2024Abandon1710NoNo
18298807THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUSApril 2023October 2024Allow1810NoNo
18126275SYNTHETIC LETHALITY AND THE TREATMENT OF CANCERMarch 2023March 2025Abandon2411NoNo
18186762Immunotherapy Methods for Patients Whose Tumors Carry a High Passenger Gene Mutation BurdenMarch 2023October 2024Allow1910NoNo
18185736IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOFMarch 2023August 2024Allow1710NoNo
18175420ANTIBODIES AGAINST TIM3 AND USES THEREOFFebruary 2023January 2025Allow2320NoNo
18173417DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESFebruary 2023January 2024Abandon1100NoNo
18171569METHODS OF DETECTING PROSTATE CANCERFebruary 2023August 2024Allow1811YesNo
18164417CHIMERIC ILT RECEPTOR COMPOSITIONS AND METHODSFebruary 2023February 2025Allow2430YesNo
18163723BIOMARKERS FOR PREDICTING TUMOR RESPONSE TO AND TOXICITY OF IMMUNOTHERAPYFebruary 2023January 2025Allow2310NoNo
18157717PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCERJanuary 2023August 2024Abandon1910NoNo
18151297APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINSJanuary 2023April 2025Abandon2720NoNo
18149881MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLSJanuary 2023April 2024Allow1510YesNo
18082368NANOPARTICLES AND DISTINCT EXOSOME SUBSETS FOR DETECTION AND TREATMENT OF CANCERDecember 2022November 2024Allow2321NoNo
18078088WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATESDecember 2022December 2024Abandon2410NoNo
18062419DETECTING NEOPLASMDecember 2022March 2024Allow1510NoNo
18057627Novel Method For Producing Low Viscous And Highly Concentrated Biopharmaceutical Drug Products In Liquid FormulationNovember 2022March 2025Abandon2720NoNo
18054307METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMANovember 2022June 2025Abandon3140NoNo
18047285VIRUS COMPOSITIONOctober 2022August 2024Allow2211NoNo
18047216METHODS OF TREATING TUMOROctober 2022October 2023Allow1210YesNo
18046565NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTSOctober 2022October 2024Abandon2420NoNo
17932259CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOFSeptember 2022August 2024Allow2320NoNo
17940883PLASMA AUTOANTIBODY BIOMARKERS FOR BASAL LIKE BREAST CANCERSeptember 2022May 2024Allow2012NoNo
17817886IMMUNE-STIMULATING IL-2 FUSION PROTEINSAugust 2022May 2023Allow1020YesNo
17817862DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESAugust 2022May 2023Abandon900NoNo
17848694RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSJune 2022November 2023Allow1710YesNo
17846966BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTIONJune 2022April 2024Abandon2111YesNo
17843852METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORSJune 2022June 2025Abandon3610NoNo
17806218CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTIONJune 2022February 2024Allow2020NoNo
17805336CANCER TREATMENTJune 2022July 2024Abandon2520NoNo
17826477BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSEMay 2022April 2025Allow3531NoNo
17752519WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATESMay 2022September 2022Allow310NoNo
17744262METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTINMay 2022February 2025Allow3340NoNo
17739317TCR, POLYPEPTIDE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHOD FOR OBTAINING TCRMay 2022November 2024Allow3131NoNo
17739308HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIESMay 2022April 2024Allow2410YesNo
17736475HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38May 2022June 2024Allow2511NoNo
17722051NON-CODING RNA FOR DETECTION OF CANCERApril 2022November 2023Abandon1930YesNo
17654801Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseasesMarch 2022September 2023Allow1810NoNo
17690634METHODS FOR THE TREATMENT OF CANCERMarch 2022June 2024Abandon2720NoNo
17639783ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYMarch 2022September 2023Allow1900NoNo
17673718NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOFFebruary 2022June 2024Allow2821YesNo
17650360COMPOSITION AND PROCESS FOR PREPARING VACCINEFebruary 2022April 2024Abandon2611NoNo
17588262HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMATJanuary 2022August 2023Allow1910NoNo
17597706IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOFJanuary 2022December 2022Allow1110NoNo
17568738BISPECIFIC SINGLE-CHAIN ANTIBODY, RECOMBINANT ONCOLYTIC VIRUS FOR EXPRESSING SAME AND VIRUS COMPOSITIONJanuary 2022August 2022Allow820YesNo
17620209ANTI-CD53 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOFDecember 2021May 2025Abandon4101NoNo
17542342HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSDecember 2021November 2023Allow2411NoNo
17542341HETERODIMERIC ANTIBODIES THAT BIND SOMATOSTATIN RECEPTOR 2December 2021April 2024Allow2811NoNo
17615735PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENESDecember 2021June 2025Abandon4301NoNo
17539030MARKER COMPOSITION FOR DIAGNOSING OR PREDICTING PROGNOSIS OF LUNG CANCER BASED ON EXOSOME OVEREXPRESSING GCC2 GENE OR PROTEINNovember 2021January 2024Allow2620NoNo
17615535MULTI-TUMOR GENE SIGNATURE FOR SUITABILITY TO IMMUNO-ONCOLOGY THERAPYNovember 2021June 2025Abandon4201NoNo
17526817ANTI-TIM-3 ANTIBODIES AND USE THEREOFNovember 2021November 2023Abandon2410NoNo
17609517Cancer stratification and treatment based on Inhibition of NOD-2November 2021June 2025Abandon4310NoNo
17515227TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINSOctober 2021December 2023Allow2520NoNo
17504452HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSOctober 2021August 2023Allow2210NoNo
17501576COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSOctober 2021July 2023Allow2110NoNo
17489885ANTIBODY BINDING TO CARBONIC ANHYDRASE AND USE THEREOFSeptember 2021August 2023Allow2220NoNo
17471526Treatment of Parkinson's DiseaseSeptember 2021May 2024Allow3210NoNo
17465968ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOFSeptember 2021October 2023Allow2611NoNo
17434359APOE GENOTYPING IN CANCER PROGNOSTICS AND TREATMENTAugust 2021January 2025Allow4121NoNo
17407264BINDING MOLECULE SPECIFIC FOR LIF AND USE THEREOFAugust 2021April 2024Allow3251NoNo
17404025OVARIAN CANCER VACCINESAugust 2021June 2023Allow2110NoNo
17393892METHODS FOR CAPTURING, ISOLATION, AND TARGETING OF CIRCULATING TUMOR CELLS AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS THEREOFAugust 2021October 2023Abandon2701NoNo
17443780Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofJuly 2021October 2023Abandon2610NoNo
17383975INHIBITORS OF ALPHA-TUBULIN ACETYLATION FOR THE TREATMENT OF PAINJuly 2021July 2023Allow2410NoNo
17379878NOVEL METHOD FOR MONITORING AND TREATING ORAL CANCERJuly 2021December 2024Abandon4101NoNo
17422227USE OF AGENTS CAPABLE OF INDUCING LC3-ASSOCIATED PHAGOCYTOSIS FOR TREATING SUSTAINED INFLAMMATION IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASEJuly 2021March 2025Abandon4420NoNo
17368674TUMOR MICROENVIRONMENT-BASED METHODS FOR ASSESSING CAR-T AND OTHER IMMUNOTHERAPIESJuly 2021September 2022Allow1530YesNo
17366769Method For Determining Responsiveness To Prostate Cancer TreatmentJuly 2021December 2023Allow2911NoNo
17359100WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATESJune 2021February 2022Allow810YesNo
17358277CONTORSBODY - A SINGLE CHAIN TARGET BINDERJune 2021September 2023Abandon2710NoNo
17353013METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASISJune 2021July 2023Allow2510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AEDER, SEAN E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
27
Examiner Affirmed
14
(51.9%)
Examiner Reversed
13
(48.1%)
Reversal Percentile
69.0%
Higher than average

What This Means

With a 48.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
199
Allowed After Appeal Filing
37
(18.6%)
Not Allowed After Appeal Filing
162
(81.4%)
Filing Benefit Percentile
20.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner AEDER, SEAN E - Prosecution Strategy Guide

Executive Summary

Examiner AEDER, SEAN E works in Art Unit 1642 and has examined 1,611 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner AEDER, SEAN E's allowance rate of 52.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AEDER, SEAN E receive 2.33 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AEDER, SEAN E is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +26.2% benefit to allowance rate for applications examined by AEDER, SEAN E. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.1% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 43.1% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 52.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 44% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 73.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.